Machine learning, predictive models, and computational biology—how AI is changing discovery workflows and probability of success.
QuantHealth has raised $45 million to expand its AI platform for simulating clinical trials before patient enrollment, aiming to reduce failure rates and accelerate drug development timelines.
QuantHealth has raised $45 million to expand its AI platform for simulating clinical trials before patient enrollment, aiming to reduce failure rates and accelerate drug development timelines.
READ MORE
Grove AI, founded in 2024, leveraged advanced voice agent technology to streamline patient recruitment for clinical trials, leading to its rapid acquisition by Hippocratic AI.
As biopharma dealmaking increasingly hinges on access to advanced datasets, the question of who owns and controls AI-generated data is emerging as a major challenge for partnerships between Big Pharma and AI-driven biotech firms.
A new report by the Peterson Health Technology Institute finds gaps and complications in how healthcare systems pay for clinical AI, warning of projected cost increases and calls for reform.
Bristol Myers Squibb (BMS) stakes a bold claim with its plan to build the life sciences industry’s largest NVIDIA-powered AI supercomputer, continuing the pharma sector’s accelerating race into large-scale artificial intelligence infrastructure.
A new McKinsey report suggests that biopharma companies must reorganize their R&D departments to fully realize AI’s potential. Without foundational structural changes, the full benefits of artificial intelligence could remain out of reach for drug developers.
Xaira Therapeutics, once a stealthy newcomer, is starting to engage external partners as it looks to validate its ambitious AI-enabled drug discovery pipeline.
The intersection of healthcare and artificial intelligence presents both opportunities and profound challenges. With AI increasingly powerful in controlled settings, questions persist about responsibility, authority, and accountability in clinical adoption.
The integration of artificial intelligence tools into mental health care is accelerating, but experts warn that clinicians are essential to ensure high-quality, ethical, and patient-centered care. This analysis explores the critical nuances that AI alone cannot address in mental health practice.
Agentic AI represents a fundamental shift from passive information providers to proactive task-doers in healthcare, potentially transforming everything from patient navigation to care coordination.
Anthropic, widely recognized as a leader in artificial intelligence, has announced its entry into drug development, raising pressing questions about AI’s potential to disrupt and redefine biopharmaceutical R&D.
